← Leaderboards
Robert A Figler
Adenosine Therapeutics, Llc
$1,624,445
Attributed
$1,624,445
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,624,445 · 3
By mechanism
R44$1,424,445 · 1
R43$200,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Adenosine Therapeutics, Llc
Same institution · by research overlap
- Robert D Thompson$4,905,559
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationPurinergic ReceptorDrug Design /Synthesis /ProductionPharmacokineticsNoninsulin Dependent Diabetes MellitusInsulin Sensitivity /ResistanceXanthinesHypoglycemic AgentsInhibitor /AntagonistLaboratory MouseLaboratory RatNonhuman Therapy EvaluationStriated MusclesImmunoglobulin EAdenosineDogsTheophyllineTissue /Cell CultureMast CellWater SolubilityDiabetes Mellitus TherapyAsthmaAdipose TissueRadiotracer
Grant awards (4)
Antagonists of A2B Receptors Improve Insulin Sensitivity$697,156
R44 · FY2005 · DK
Antagonists of A2B Receptors Improve Insulin Sensitivity$727,289
R44 · FY2004 · DK
ANTAGONIST OF A2B ADENOSINE RECEPTORS FOR ASTHMA$100,000
R43 · FY2001 · AI
Antagonists of A2B Receptors Improve Insulin Sensitivity$100,000
R43 · FY2001 · DK